If Roche execs thought they escaped having a dogfight in India over their patent for the Herceptin breast cancer treatment, they were mistaken. The Indian Health Ministry has moved to revoke the patent even though the Department of Industrial Policy and Promotion rejected a plea for a compulsory license by patient advocates to make the medicine more affordable, The Times of India reports. The move by the Health Ministry, which is taking this step in the public interest, is apparently a highly unusual step that has been taken only twice in the past.